Skip to content
DataLookout
Menu

NCT06386874

EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

StatusTerminated
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Poor accrual Show 6 more changesShow less
    • Eligibility criteria expanded, about 25 words
    • Final enrollment: 62 participants (planned 122)
    • Primary completion date changed from estimate of Jul 2026 to Dec 26, 2025
    • Study completion date changed from estimate of Oct 2026 to Apr 7, 2026
    • Secondary endpoints: details revised at 3 of 16 entries
    • Site details revised at 14 of 14 sites
  2. Minor Site details revised at 1 of 14 sitesv5
  3. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
    • Study sites: 1 to 14
    • Start date changed from estimate of Aug 2024 to Aug 20, 2024
    • Interventions: BQ 3.0 (Device), BQ 3.0 system (Device) to Q Therapeutic System (BQ 3.0) - Active (Device), Q Therapeutic System (BQ 3.0) - Sham (Device)
    • Secondary endpoints: 9 to 16
    • Study description expanded, about 435 words
  4. Minor Start date: Jul 2024 to Aug 2024v3
  5. Notable Lead sponsor: [Redacted] to BrainQ Technologies Ltd.v2 Show 5 more changesShow less
    • Trial status: Withheld to Not Yet Recruiting
    • Primary completion date: Jul 2026
    • Study completion date: Oct 2026
    • Start date: Jul 2024
    • Study title shortened, about 2 words
  6. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in Modified Rankin Scale
Timeframe: 4 to 21 days following an ischemic stroke to 90-day post-stroke

Secondary (16)

Ordinal shift analysis of the mRS (trichotomized at 0-1, 2, 3-6) (Key Secondary Effectiveness Endpoint)
Change from Baseline in Modified Rankin Scale (Key Secondary Effectiveness Endpoint)
Proportion of subjects achieving functional independence (mRS score of 0-2) (Key Secondary Effectiveness Endpoint)
Stroke Impact Scale Hand Domain (Lead Secondary Endpoint)
Stroke Impact Scale 16
Show 11 moreShow less
10-meter Walk Test
Box and Block Test
Evaluation of 5-level EQ-5D
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
Nine-Hole Peg Test
The proportion of subjects within those in the active group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment.
The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as a mRS score of 0-1 at the 90-day post-stroke assessment and had an mRS >1 at 180-day post-stroke
The proportion of patients within those in the active group who continued to receive treatments in Stage 2, who achieved an excellent outcome defined as mRS score of 0-1 at the 180-day post-stroke assessment and had an mRS >1 at 270 days post-stroke.
Ordinal shift analysis of the mRS (4 levels at 0, 1, 2, 3-6) from the 90-day post-stroke assessment to 180-day post-stroke assessment, within those in the active group who continued to receive treatments in Stage 2
The proportion of patients who improved by at least 1 level on the mRS from the 90-day post-stroke assessment to 180-day post-stroke assessment, within those in the active group who continued to receive treatments in Stage 2.
The proportion of subjects within those in the sham group who continued to receive treatments in Stage 2, achieving an excellent outcome (defined as a mRS of 0-1) at the 180-day post-stroke assessment, and had an mRS >1 at 90 days post-stroke.

Arms and interventions

BQ 3.0 Sham Stimulation GroupSham comparator

Q Therapeutic System (BQ 3.0) sham stimulation group: Device used: Q Therapeutic System (BQ 3.0) In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 3.0 (frequency and intensity parameters will be set to zero so that no stimulation is delivered) including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

BQ 3.0 Active Stimulation GroupActive comparator

Q Therapeutic System (BQ 3.0) active stimulation group: Device used: Q Therapeutic System (BQ 3.0) In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

Devices: Q Therapeutic System (BQ 3.0) - Sham, Q Therapeutic System (BQ 3.0) - Active

Sites

14 sites in 1 country